← Leaderboards
Rayjean J. Hung
Dartmouth College
$4,396,512
Attributed
$5,890,846
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2017–24$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,344,154 · 6
By mechanism
U19$24,344,154 · 6
Top collaborators
- Christopher I. Amos20 shared
- Xihong Lin20 shared
- Paul Joseph Brennan14 shared
- Mattias Alexander Johansson6 shared
Most similar at Dartmouth College
Same institution · by research overlap
- Madeline A. Dalton$10,243,343
- Brock Clarke Christensen$12,717,693
- Margaret Rita Karagas$80,214,192
- Terri D Lewinson$1,114,612
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Lung”
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
- Greg Yothers · University Of Chicago$35,003,821
- Lynn Briscoe · Leidos Biomedical Research, Inc.$26,085,158
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,658,268
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- John Freymann · Leidos Biomedical Research, Inc.$14,011,208
Research focus
Malignant Neoplasm Of LungCancer RiskCancer EtiologyScreeningProgramsBiological MarkersEpidemiologyRisk AssessmentInternationalCohortCancer PatientCessation Of LifeMortalityGeneticHigh RiskCollaborationsResearch PersonnelEnvironmental Risk FactorMalignant NeoplasmsSmoking BehaviorTranslatingComputed Tomography ScreeningSiteParticipant
Grant awards (29)
Integrative Analysis of Lung Cancer Etiology and Risk$2,656,017
U19 · FY2024 · CA
Translating Molecular and Clinical Data to Biomarker-Informed Screening Pathway$761,567
U19 · FY2024 · CA · contact PI
Core-002$236,876
U19 · FY2024 · CA
Integrative Analysis of Lung Cancer Etiology and Risk$73,910
U19 · FY2024 · CA
Translating Molecular and Clinical Data to Biomarker-Informed Screening Pathway$19,334
U19 · FY2024 · CA · contact PI
Core-002$7,149
U19 · FY2024 · CA
Integrative Analysis of Lung Cancer Etiology and Risk$2,910,518
U19 · FY2023 · CA
Translating Molecular and Clinical Data to Biomarker-Informed Screening Pathway$662,868
U19 · FY2023 · CA · contact PI
Core-002$312,212
U19 · FY2023 · CA
Integrative analysis of lung cancer etiology and risk$2,234,679
U19 · FY2022 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$393,292
U19 · FY2022 · CA · contact PI
Admin-Core-001$228,309
U19 · FY2022 · CA
Integrative analysis of lung cancer etiology and risk$2,334,007
U19 · FY2021 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$496,067
U19 · FY2021 · CA · contact PI
Admin-Core-001$238,989
U19 · FY2021 · CA
Administrative Supplement: Integrative analysis of lung cancer etiology and risk$228,106
U19 · FY2021 · CA
Admin-Core-001$228,106
U19 · FY2021 · CA
Integrative analysis of lung cancer etiology and risk$2,605,399
U19 · FY2020 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$566,670
U19 · FY2020 · CA · contact PI
Admin-Core-001$298,234
U19 · FY2020 · CA
Integrative analysis of lung cancer etiology and risk$2,306,176
U19 · FY2019 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$491,638
U19 · FY2019 · CA · contact PI
Admin-Core-001$229,912
U19 · FY2019 · CA
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies$147,830
U19 · FY2018 · CA
Integrative analysis of lung cancer etiology and risk$2,783,512
U19 · FY2017 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$494,898
U19 · FY2017 · CA · contact PI
Admin-Core-001$212,658
U19 · FY2017 · CA
Integrative analysis of lung cancer etiology and risk$173,154
U19 · FY2017 · CA
Translating Molecular and Clinical Data to Population Lung Cancer Risk Assessment$12,067
U19 · FY2017 · CA · contact PI